Tesamorelin and ipamorelin both get filed under “growth hormone peptides,” and that shorthand hides the most useful thing about them: they raise growth hormone through two different doors. One imitates the hormone that tells your pituitary to release GH; the other imitates hunger signaling to do it. That difference is why they are sometimes compared, sometimes stacked, and suited to different research goals.
Tesamorelin: The GHRH Analog
Tesamorelin is a synthetic analog of GHRH (growth-hormone-releasing hormone) — the natural signal your hypothalamus sends to tell the pituitary to release growth hormone. By mimicking that signal, tesamorelin prompts a GH release that follows the body’s own rhythm rather than overriding it. Its standout feature in the research is a specific effect on visceral fat — the deep abdominal fat around organs.
It is also the one with real regulatory standing: tesamorelin is approved as Egrifta for reducing excess visceral fat in HIV-associated lipodystrophy. In those trials it reduced visceral adipose tissue meaningfully (on the order of 15–18%) without being a general weight-loss drug — the effect was targeted at that deep fat compartment. Our tesamorelin and belly fat guide covers that research.
Ipamorelin: The Selective Secretagogue
Ipamorelin works through a completely different receptor. It is a ghrelin receptor agonist — it mimics ghrelin, the so-called hunger hormone, which is also a potent trigger for growth hormone release. Ipamorelin’s claim to fame is selectivity: unlike older growth-hormone-releasing peptides, it was shown to prompt a clean GH pulse without meaningfully raising cortisol or prolactin, which is why it is described as one of the gentler, more targeted secretagogues.
That cleaner profile is the whole appeal. Ipamorelin is studied as a mild, well-tolerated way to nudge natural GH release, rather than a heavy-handed intervention. It does not have tesamorelin’s human approval — it is a research compound — and it is not specifically a visceral-fat tool.
Tesamorelin imitates the GH-releasing hormone; ipamorelin imitates hunger signaling. Two different doors into the same room — which is exactly why researchers sometimes open both at once.The mechanism split in one line
The Key Difference
The distinction comes down to which natural signal each one copies. Tesamorelin is a GHRH analog — it pushes the same button the hypothalamus normally pushes. Ipamorelin is a ghrelin mimic — it pushes a second, independent button that also triggers GH. Because the pituitary responds to both signals, the two peptides reach the same destination (more growth hormone) by separate routes.
Practically, that shapes how each is used. Tesamorelin is the more clinically validated, targeted tool, with a specific, approved visceral-fat effect behind it. Ipamorelin is the milder, more general-purpose secretagogue prized for its clean side-effect profile. One is a precise instrument with a narrow proven use; the other is a gentle all-rounder. Neither is interchangeable with the other.
Why They Get Stacked
Here is where the mechanism difference becomes a feature. Because GHRH analogs and ghrelin agonists work through separate pathways, combining the two classes can produce a larger, synergistic GH release than either alone — pushing both pituitary buttons at once. This is the logic behind the popular CJC-1295 and ipamorelin stack, where a GHRH analog is paired with ipamorelin. Tesamorelin, as another GHRH analog, follows the same complementary principle when discussed alongside ipamorelin.
The takeaway: these are not really competitors so much as two halves of a potential pairing. If the research goal is targeted visceral-fat work, tesamorelin stands on its own evidence; if it is a gentle GH nudge or a synergistic stack, ipamorelin is the complementary piece. For the broader context, see our best peptides for muscle growth guide.
TrueLabs carries both tesamorelin and ipamorelin as Canadian-sourced, third-party-tested research peptides with published certificates of analysis.
FAQ
Tap a question to reveal the answer.
What is the difference between tesamorelin and ipamorelin?
They raise growth hormone through different mechanisms. Tesamorelin is a GHRH analog that mimics the hormone telling the pituitary to release GH. Ipamorelin is a ghrelin receptor agonist that triggers GH through the hunger-signaling pathway instead. Same end result, two separate routes.
Is tesamorelin or ipamorelin better for fat loss?
Tesamorelin has the stronger evidence for a specific target: deep visceral abdominal fat, where it is actually approved for a medical use. Ipamorelin is a gentler, general GH secretagogue without a dedicated visceral-fat indication. For targeted visceral fat research, tesamorelin is the better-validated tool.
Can you take tesamorelin and ipamorelin together?
They are sometimes studied together precisely because they work through different pathways, which can produce a larger, synergistic GH release than either alone. This is the same logic behind the CJC-1295 and ipamorelin stack. As always, combining compounds makes effects harder to isolate, and both remain research-use-only.
Is ipamorelin a growth hormone?
No. Ipamorelin does not contain growth hormone; it is a secretagogue, meaning it prompts your own pituitary to release more of its natural GH. That is different from injecting growth hormone directly, and it is part of why secretagogues are studied as a gentler approach.
Is tesamorelin approved by the FDA?
Yes, for a specific use. Tesamorelin is approved as Egrifta to reduce excess visceral fat in people with HIV-associated lipodystrophy. That approval does not extend to general weight loss or bodybuilding, and the research-chemical version is sold for laboratory study only.
Does ipamorelin raise cortisol?
Minimally, and that is its signature advantage. Unlike older growth-hormone-releasing peptides, ipamorelin was shown to prompt a clean GH pulse without meaningfully increasing cortisol or prolactin. This selectivity is the main reason it is considered one of the better-tolerated secretagogues.
Which is safer, tesamorelin or ipamorelin?
They have different profiles rather than a simple ranking. Tesamorelin has the most human safety data because it is an approved drug, while ipamorelin is valued for its clean, selective action but lacks that approval. Both are research compounds here, and neither is a sanctioned growth-hormone therapy.
Related reading
- CJC-1295 and ipamorelin stack
- Tesamorelin and belly fat
- Best peptides for muscle growth
- Peptides for men
References
- Falutz J, et al. Tesamorelin, a GHRH analog, and visceral adipose tissue in HIV. New England Journal of Medicine, 2007;357:2359.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139:552. PMID 9849822.
- Egrifta (tesamorelin) FDA prescribing information.
Products referenced are sold strictly for laboratory and research use only. They are not approved for human or veterinary use (except tesamorelin’s specific approved indication, which does not apply to research material), are not dietary supplements, and nothing here is medical advice, a protocol, or dosing guidance. Always consult the current scientific literature and comply with local regulations.